These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 20490381)

  • 1. [Antifungal therapy for infants, children and adolescents with suspected or documented invasive fungal infection].
    Odio CM
    Drugs Today (Barc); 2010 Apr; 46 Suppl C():33-46. PubMed ID: 20490381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prevention of fungal infections in children and adolescents with cancer].
    Groll AH; Ritter J; Müller FM
    Klin Padiatr; 2001 Sep; 213 Suppl 1():A50-68. PubMed ID: 11577364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
    Jensen RH
    Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Fungal infections in oncohematology: the role of prophylaxis].
    Sobrevilla Calvo P
    Drugs Today (Barc); 2010 Apr; 46 Suppl C():7-11. PubMed ID: 20490377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.
    Rex JH; Walsh TJ; Sobel JD; Filler SG; Pappas PG; Dismukes WE; Edwards JE
    Clin Infect Dis; 2000 Apr; 30(4):662-78. PubMed ID: 10770728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developments in the epidemiolgy of invasive fungal infections - implications for the empiric and targeted antifungal therapy.
    Hof H
    Mycoses; 2008; 51 Suppl 1():1-6. PubMed ID: 18471155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.
    Krcmery V; Barnes AJ
    J Hosp Infect; 2002 Apr; 50(4):243-60. PubMed ID: 12014897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome.
    Safdar A; van Rhee F; Henslee-Downey JP; Singhal S; Mehta J
    Bone Marrow Transplant; 2001 Nov; 28(9):873-8. PubMed ID: 11781648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of mycoses in surgical patients -- review of the literature.
    Holzheimer RG; Dralle H
    Eur J Med Res; 2002 May; 7(5):200-26. PubMed ID: 12069912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections.
    Groll AH; Walsh TJ
    Mycoses; 2006; 49 Suppl 1():7-16. PubMed ID: 16961576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Drugs used in prophylaxis and treatment of fungal infections in immunosuppressed children].
    Balwierz W
    Przegl Lek; 2004; 61 Suppl 2():89-94. PubMed ID: 15686055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fungal infections in cancer patients: an escalating problem.
    Samonis G; Bafaloukos D
    In Vivo; 1992; 6(2):183-93. PubMed ID: 1525339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posaconazole: an extended-spectrum triazole antifungal agent.
    Schiller DS; Fung HB
    Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy of invasive organ mycoses in patients with systemic hematologic diseases].
    Karthaus M; Böhme A
    Wien Med Wochenschr; 2001; 151(3-4):80-8. PubMed ID: 11789423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital.
    Bedini A; Venturelli C; Mussini C; Guaraldi G; Codeluppi M; Borghi V; Rumpianesi F; Barchiesi F; Esposito R
    Clin Microbiol Infect; 2006 Jan; 12(1):75-80. PubMed ID: 16460550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
    Fera MT; La Camera E; De Sarro A
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation.
    Koh LP; Kurup A; Goh YT; Fook-Chong SM; Tan PH
    Am J Hematol; 2002 Dec; 71(4):260-7. PubMed ID: 12447954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of documented and suspected neutropenia-associated invasive fungal infections.
    De Pauw BE
    J Chemother; 2001 Nov; 13 Spec No 1(1):181-92. PubMed ID: 11936364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voriconazole -- better chances for patients with invasive mycoses.
    Ghannoum MA; Kuhn DM
    Eur J Med Res; 2002 May; 7(5):242-56. PubMed ID: 12069915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.